Mylan

Notizia
KINECT 4 Study; KindredBio Announces Results; Mylan and Aspen’s Launch; EMA investigates; Amgen’s...

KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms Neurocrine Biosciences, Inc. announced new long-term data from the KINECT 4 Phase III open-label study demonstr...


Gilead faces lawsuit; Herceptin stalled; Lilly revs up, Abemaciclib gets nod; Key Humira patent g...

Gilead faces revived lawsuit claiming it sidestepped FDA with HIV drug imports Gilead Sciences thought it had prevailed in a whistleblower lawsuit alleging it circumvented FDA rules to use a China-...


Personalized Medicine
Valeant’s $50M; Sanofi vows; Top pharmas team up; PhRMA expels

Shadowed by nearly $30B in debt, Valeant's $50M guidance raise looks pretty paltry Faced with a crippling pile of debt, Valeant on Tuesday slightly increased its 2017 earnings guidance, one small ...


Dengvaxia study; Opdivo racks up; FDA issues plant; Teva’s Rimsa fraud; Mission bags Fox grant

Malaysia calls for phase 4 Dengvaxia study before considering full approval Already struggling to meet initial expectations, Sanofi Pasteur's dengue vaccine Dengvaxia will have to undergo phase 4 t...


Biogen triumphs; Lilly, Pfizer, Ipsen back; Court nixes; Mylan EpiPen recall

Biogen triumphs in latest Tecfidera patent dispute Biogen has prevailed in a patent squabble with Denmark’s Forward Pharma over multiple sclerosis med Tecfidera—but the decision may not actually he...


Mylan closing Illinois plant; Insys spends $24M; Roche’s Ocrevus; Greece’s corruption prose...

Mylan closing Illinois plant, cutting 90 jobs as part of slim-down after Meda buyout Mylan has been in the midst of cutting about 3,500 jobs to decrease costs and refocus after its $7 billion buyou...


NPPA slams; Japan Joins Trump; PCI Pharma Announces Expansion; Merck opens plant; Mylan and Bioco...

NPPA slams pharma giants for overcharging The price regulator in the pharmaceutical industry, National Pharmaceutical Price Authority (NPPA) has discovered that the leading Pharma companies are ove...


Pfizer uses; FDA approves; EMA approves; Mylan launches

For Inflectra launch, Pfizer uses 'hybrid model' to home in on HCPs Pfizer hit the market with Inflectra, a biosimilar of Johnson & Johnson's Remicade. And with the launch came not only the beg...


Novartis eyes; Pfizer considers cashing; Mylan pushes to seal $465M; Valeant with Takeda for deal

Novartis eyes $8B Amneal buy Novartis is weighing a deal for the generics maker Amneal Pharmaceuticals to expand its already-hefty Sandoz unit, at a time when two of its biggest rivals in the field...


Fresenius Kabi introduced Bivalirudin; Envigo Launches; Mylan’s MAA accepted; Pricing hit p...

Fresenius Kabi introduced Bivalirudin for Injection Fresenius Kabi announced that it has introduced Bivalirudin for Injection in the United States, which is an anticoagulant, and a generic alternat...


Editor's Pick
Can denovoSkin Be A Lifesaver for Burn Victims?

Burn is a global public health problem, causing more than 180,000 deaths per year acros...

NexoBrid and its Awaiting US Approval

A Burn takes place when the skin comes into contact with a heat source. Burns can occur...

New Clinical Developments in the Pulmonary Arterial Hypertension Treatment Do...

Pulmonary arterial hypertension is a progressive disease of the lung vascular system, p...

Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.